Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Key Inclusion Criteria of the master protocol:

• Able and willing to sign the informed consent (IC)

• Patients with a diagnosis of AD and onset of disease for at least 1 year

• Moderate to severe AD

Key Exclusion Criteria of the master protocol:

• Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)

• Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG

• Participant with any other active inflammatory skin disease

• Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)

• Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)

Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements